iShares U.S. Healthcare ETF News - September 2026
GRAIL Wins 7-2 FDA Panel Support for Galleri Approval
An advisory committee to the U.S. Food and Drug Administration (FDA) voted 7-2 in favor of GRAIL’s premarket approval application for its Galleri multi-cancer...
Novo Nordisk Signs $1.33B Nanexa Deal for Long-Acting Obesity and Diabetes Drugs
Novo Nordisk has signed a licensing agreement with Swedish drug delivery firm Nanexa worth up to €1.165 billion ($1.33 billion). The deal gives Novo Nordisk...
Eli Lilly Wins FDA Approval for Onswik, Slashing Annual Insulin Injections
The U.S. Food and Drug Administration approved Eli Lilly and Company’s Onswik (insulin efsitora alfa-gobe). This once-weekly basal insulin injection treats...
Ultragenyx Wins FDA Approval for $3.95M Therapy, First for Sanfilippo Syndrome
The U.S. Food and Drug Administration (FDA) granted full approval to Ultragenyx Pharmaceutical's gene therapy, FAYUVI (UX111). This one-time intravenous...
Novo Nordisk wins China approval for Wegovy, first GLP-1 for liver disease
Novo Nordisk announced Thursday that Chinese regulators approved its drug Wegovy for a new indication. The approval covers the treatment of metabolic...
FDA Appoints First AI Chief, Aiming to Modernize Healthcare Regulation
The U.S. Food and Drug Administration (FDA) created the role of Deputy Commissioner for Technology and Artificial Intelligence. Jared Seehafer will serve as...
Eli Lilly buys Merida for $2.88B, diversifying beyond blockbuster obesity drugs
Eli Lilly will acquire Merida Biosciences in an all-cash deal valued at up to $2.88 billion. This transaction marks the pharmaceutical giant’s 13th acquisition...